Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Current Ratio
since 2005

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Merck & Co. Inc., current ratio, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


The current ratio exhibited considerable fluctuation between 2005 and 2025. Initially, the ratio decreased from 1.58 in 2005 to a low of 1.20 in 2006, followed by a slight recovery to 1.23 in 2007. A moderate increase was then observed through 2010, peaking at 1.86. Subsequently, the ratio continued to climb, reaching its highest point of 2.04 in 2011. The period between 2012 and 2015 saw a decline, bottoming out at 1.55 in 2015. A brief recovery occurred in 2016, but the ratio then experienced a more pronounced downward trend through 2018, falling to 1.17. A slight increase was noted in 2019, but this was followed by a significant drop to 1.02 in 2020. The ratio recovered somewhat in 2021 and 2022, reaching 1.47 and 1.25 respectively, before concluding at 1.36 in 2025.

Overall Trend
The current ratio demonstrated a cyclical pattern over the twenty-year period. While there were periods of sustained growth, such as between 2006 and 2011, these were interspersed with periods of decline. The latter half of the period, particularly 2016-2020, showed a more pronounced weakening of the ratio.
Periods of Strength
The strongest performance in terms of the current ratio occurred between 2010 and 2011, with values consistently above 1.80. This suggests a strong liquidity position during these years, with a substantial margin of current assets covering current liabilities.
Periods of Weakness
The lowest point for the current ratio was observed in 2020, at 1.02. This indicates a potential liquidity concern, where current liabilities nearly equaled current assets. The period between 2017 and 2020 generally showed a weakening liquidity position.
Recent Performance
The current ratio experienced a recovery in 2021 and 2022, but this momentum slowed in 2023 and 2024. The ratio concluded at 1.36 in 2025, suggesting a moderate liquidity position, but not as strong as observed in the earlier part of the analyzed period.
Volatility
The current ratio exhibited significant volatility throughout the period. This suggests that the company’s short-term liquidity position was subject to considerable change, potentially influenced by factors such as working capital management, seasonal fluctuations, or strategic investments.

Comparison to Competitors

Merck & Co. Inc., current ratio, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Merck & Co. Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)